



**IKARIA RECEIVES AWARD FOR EXCELLENCE  
BY NEW JERSEY BUSINESS & INDUSTRY ASSOCIATION**

**Clinton, NJ, October 21, 2009**– Ikaria Holdings, Inc. today announced that it has been awarded the 2009 Award for Excellence in Business Expansion by the New Jersey Business & Industry Association (NJBIA), the largest state-run employer association in the United States. Ikaria earned the award based on criteria including increased productivity and revenues, as well as the net creation of new jobs.

“We are delighted that the New Jersey Business & Industry Association has recognized Ikaria for its contribution to the economic growth of New Jersey,” said Daniel Tass, Chairman and CEO of Ikaria. “This award acknowledges the strides we’ve made through strategic hiring of key positions in building a strong and sustainable business that is uniquely devoted to delivering novel treatments to fulfill the unmet medical needs of critically ill patients.”

Ikaria was honored at the Annual NJBIA Awards Dinner on October 20, 2009.

**About Ikaria Holdings, Inc.**

Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company’s lead product, INOMAX® (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America, Australia, Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOMAX, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. The company also recently acquired the exclusive worldwide licenses to BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction, as well as to a portfolio of investigational compounds focused on vascular leakage for a range of critical care conditions, such as acute lung and kidney injury. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Please visit [www.ikaria.com](http://www.ikaria.com).

###